期刊文献+

胶质瘤染色体1p/19q联合缺失特点分析 被引量:6

Characteristics of combining loss of heterozygosity of 1p/19q in glioma
原文传递
导出
摘要 目的 研究胶质瘤1p/19q联合缺失与患者性别、年龄、肿瘤部位及病理分型是否具有相关性.方法 用荧光原位杂交法(Fluorescence in situ hybridization,FISH)对2009年1月至12月的138例胶质细胞瘤患者术后胶质瘤标本进行1P和19q缺失状态分析,男性80例,女性58例;年龄17~68岁,平均41.6岁.利用X2检验分析不同性别、年龄、肿瘤部位、病理类型的1p/19q联合缺失是否有差异.结果 星形细胞肿瘤(22.2%)的1p/19q联合缺失率显著低于少枝胶质细胞肿瘤(81.3%)和少枝星形细胞肿瘤(55.8%)(P<0.01),少枝胶质细胞肿瘤的1p/19q联合缺失率高于少枝星形细胞肿瘤(P<0.05).额叶胶质瘤的1p/19q联合缺失率(61.8%)显著高于颢叶(31.8%)和岛叶(34.6%)(P<0.05).1p/19q联合缺失与患者的性别、年龄无明显相关性.结论 1p/19q联合缺失主要与胶质瘤的病理类型和部位相关,与患者的年龄和性别无明显相关性. objectives To find possible factors correlated with combined loss of heterozygosity (LOH)of 1 P and 19q.Methods The status of 1 P and 19q of 138 glioma specimen from January 2009 to December 2009 was evaluated by Fluorescence in situ hybridization(FISH)method,and the frequencies of combining LOH of 1 p/19q were compared between different pathologies,brain sub-regions,genders and ages.Results The frequencies of combined LOH of 1P and 19q of oligodendroglial(81.3%)and oligoastrocytic tumors(55.8%)were significantly higher than that of agtrocytic tumor(22.2%)(P<0.01),and the frequency of oligodendroglial tumor was significantly higher than that of oligoastrocytic tumor (P<0.05).The frequency of combining LOH of 1P and 19q in frontal lobe(61.8%)was higer than that in temporal(31.8%)and insular lobes(34.6%)(P<0.05).Conclusion Combining LOH of 1P and 19q has significant correlation with the pathologies and brain sub-regions.
出处 《中华外科杂志》 CAS CSCD 北大核心 2010年第11期852-855,共4页 Chinese Journal of Surgery
基金 国家973计划专项课题资助项目(2007CB512503)
关键词 胶质瘤 荧光原位杂交 1p/19q联合缺失 Glioma In situ hybridization,fluorescence 1p/19q loss of heterozygosity
  • 相关文献

参考文献14

  • 1Richard D,Kaloshi G,Amiel-Benouaich A,et al.Dynamic history of low-grade gliomas before and after temozolomide treatment.Ann Neural,2007,61:484-490.
  • 2Bouvier C,Roll P,Quilichini B,et al.Deletions of chromosomes 1p and 19q are detectable on frozen smears of gliomas by FISH:usefulness for stereotactic biopsies.J Neurooncol,2004,68:141-149.
  • 3Weller M,Berger H,Hartmann C,et al.Combined 1p/19q loss in oligodendroglial tumors:predictive or progrtostic biomarker?Clin Cancer Res,2007,13:6933-6937.
  • 4Central nervous system cancers,NCCN clinical practice guidelines in oncology,2010,v.1:9-10.
  • 5Nagasaka T,Gunji M,Hosokai N,et al.FISH 1p/19q deletion/imbalance for molecular subclassification of glioblastoma.Brain Tumor Pathol,2007,24:1-5.
  • 6Louis DN,Ohgaki H,Wiestler OD,et al.The 2007 WHO classification of tumours of the central nervous system.Acta Neuropathol,2007,114:97-109.
  • 7Cairncross JG,Ueki K,Zlatescu MC,et al.Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.J Natl Cancer Inst,1998,90:1473-1479.
  • 8Jenkins RB,Blair H,Ballman KV,et al.A t(1;19)(q10;p10)mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.Cancer Res,2006,66:9852-9861.
  • 9Iwamoto FM,Nicolardi L,Demopoulos A,et al.Clinical relevance of 1P and 19q deletion for patients with WHO grade 2 and 3 gliornas.J Neurooncol,2008,88:293-298.
  • 10李守巍,袁芳,江涛,王忠诚.变性高效液相色谱检测少突胶质细胞瘤1p杂合性缺失[J].中国康复理论与实践,2009,15(2):120-122. 被引量:2

二级参考文献19

  • 1何杰,郑声琴,乔颖娟,姚青,郭庆明,魏晓莹,黄培林.少突胶质细胞肿瘤染色体1p、19q和10q杂合性缺失与临床预后的关系[J].临床与实验病理学杂志,2006,22(4):444-448. 被引量:10
  • 2Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004[J]. CA Cancer J Clin,2004,54:8-29.
  • 3Kleihues P, Cavenee WK. World Health Organization Classification of Tumours[M]. Lyon: IARC Press,2000.
  • 4Cairneross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in pa tients with anaplastic oligodendrogliomas[J]. J Natl Cancer Inst, 1998,90 : 1473-1479.
  • 5Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms lp and 19q as predictors of survival in oligoden-drogliomas, astrocytomas, and mixed oligoastrocytomas [J].J Clin Oncol,2000,18:636-645.
  • 6Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome lp and radiotherapy plus chemotherapy in patients with oligodendrogliomas[J]. Int J Radiat Oncol Biol Phys, 2000,48 : 825-830.
  • 7McDonald JM, See SJ, Tremont IW, et al. The prognostic impact of histology and lp/19q status in anaplastic oligoden droglial tumors[J]. Cancer,2005,104:1468-1477.
  • 8Ino Y, Zlatescu MC, Sasaki H, et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome lp loss [J]. J Neurosurg,2000,92:983-990.
  • 9van den Bent MJ, Looijenga LH, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features[J].Cancer, 2003,97:1276-1284.
  • 10Homma T, Fukushima T, Vaccarella S, et al. Correlation among pathology, genotype, and patient outcomes in glio blastoma[J].J Neuropathol Exp Neurol,2006,65:846-854.

共引文献1

同被引文献63

  • 1何杰,郑声琴,乔颖娟,姚青,郭庆明,魏晓莹,黄培林.少突胶质细胞肿瘤染色体1p、19q和10q杂合性缺失与临床预后的关系[J].临床与实验病理学杂志,2006,22(4):444-448. 被引量:10
  • 2张淑坤,卢德宏,朴月善,蔡彦宁,徐庆中.即时荧光定量PCR微卫星分析技术检测少突胶质细胞肿瘤染色体1p/19q杂合性缺失[J].中华病理学杂志,2006,35(12):731-734. 被引量:9
  • 3Jeon YK,Park K,Park CK,et al.Chromosome 1p and 19q status and p53and p16 expression patterns as prognostic indicators of oligodendroglial tumors:a clinicopathological study using fluorescence in situ hybridization.Neuropathology,2007,27:10-20.
  • 4Kim SH,Kim H,Kim TS.Clinical,histological,and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors.Acta Neuropathol,2005,110:27-38.
  • 5Brandes AA,Tosoni A,Cavallo G,et al.Correlations between O6-methylguanine DNA methyltransferase promoter methylation status,1p and 19q deletions,and response to temozolomide in anaplastic and recurrent oligodendroglioma:a prospective GICNO study.J Clin Oncol,2006,24:4746-4753.
  • 6M(o)llemann M,Wolter M,Felsberg J,et al.Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.Int J Cancer,2005,113:379-385.
  • 7Hermisson M,Klumpp A,Wick W,et al.O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.J Neurochem,2006,96:766-776.
  • 8Dumenco LL,Allay E,Norton K,et al.The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanineDNA alkyltransferase.Science,1993,259:219-222.
  • 9Baer JC,Freeman AA,Newlands ES,et al.Depletion of O6alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.Br J Cancer,1993,67:1299-1302.
  • 10Qian XC,Brent TP.Methylation hot spots in the 5' flanking region denote silencingofthe O6-methylguanine-DNA methyltransferase gene.Cancer Res,1997,57:3672-3677.

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部